Levi Edi, Mohammad Ramzi, Kodali Udayini, Marciniak Dorota, Reddy Sudha, Aboukameel Amro, Sarkar Fazlul H, Kucuk Omer, Rishi Arun K, Majumdar Adhip P N
Veterans Affairs Medical Center, Pathology and Laboratory Medicine Service, Wayne State University School of Medicine, Detroit, MI 48201, USA.
Anticancer Res. 2004 Sep-Oct;24(5A):2885-91.
EGF Receptor Related Protein (ERRP), a recently identified negative regulator of EGF-receptor (EGFR), has been shown to inhibit growth of colon cancer xenograft tumors in SCID mice. However, the mechanisms by which ERRP exerts its anti-tumor properties are poorly understood The current investigation was undertaken to delineate the inhibitory mechanisms that are triggered by ERRP.
For in vivo experiments, recombinant ERRP (20 microg/mouse) or an equivalent volume of vehicle was injected (away from the tumor site) every other day for 10 days to SCID mice xenotransplanted with the colon cancer cell line HCT-116 Tumor explants were obtained for further immunohistochemical analysis. For in vitro studies, the HCT-116 cell line was incubated with recombinant ERRP and apoptosis markers and cell cycle changes were evaluated.
Recombinant ERRP caused marked inhibition of tumor growth. This was accompanied by increased apoptosis and attenuation of ERK1/2 and Akt activities. Exposure of HCT-116 cells to recombinant ERRP for 24 hours caused apoptosis and cell cycle arrest at G0/1-phase. Induction of apoptosis was evidenced by increased levels of cleaved caspase-3, PARP proteins and acridine orange staining.
Our findings reveal a pro-apoptotic property of ERRP both in vitro and in vivo. We propose that ERRP functions by inhibiting the activation of the EGF-receptor signaling and its downstream effectors such as ERK and Akt kinases, underscoring the potential of ERRP for the treatment of colorectal cancer where the EGF pathway is known to be activated.
表皮生长因子受体相关蛋白(ERRP)是最近发现的表皮生长因子受体(EGFR)的负调控因子,已被证明可抑制SCID小鼠体内结肠癌异种移植瘤的生长。然而,ERRP发挥其抗肿瘤特性的机制尚不清楚。目前的研究旨在阐明ERRP引发的抑制机制。
在体内实验中,每隔一天向移植了结肠癌细胞系HCT-116的SCID小鼠(远离肿瘤部位)注射重组ERRP(20微克/小鼠)或等量的载体,共注射10天。获取肿瘤外植体用于进一步的免疫组织化学分析。在体外研究中,将HCT-116细胞系与重组ERRP一起孵育,并评估凋亡标志物和细胞周期变化。
重组ERRP显著抑制肿瘤生长。这伴随着凋亡增加以及ERK1/2和Akt活性的减弱。将HCT-116细胞暴露于重组ERRP 24小时导致凋亡和细胞周期停滞在G0/1期。凋亡的诱导通过裂解的半胱天冬酶-3、PARP蛋白水平的增加和吖啶橙染色得以证明。
我们的研究结果揭示了ERRP在体外和体内均具有促凋亡特性。我们提出ERRP通过抑制表皮生长因子受体信号及其下游效应物如ERK和Akt激酶的激活来发挥作用,这突出了ERRP在治疗已知表皮生长因子途径被激活的结直肠癌方面的潜力。